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doi:10.1016/j.ejvs.2011.03.010Abstract Objectives: To describe duplex ultrasound (DUS) outcomes 12 months following
ultrasound-guided foam sclerotherapy (UGFS) of recurrent great saphenous varicose veins
(GSVV).
Methods: A consecutive series of UK National Health Service patients underwent serial DUS
examinations following UGFS with 3% sodium tetradecyl sulphate for symptomatic recurrent
GSVV.
Results: 91 treated legs (CEAP C2/3 58, C4 21, C5 8, C6 4) belonging to 73 patients (24 male) of
median age 58 (range 32e86) years were enrolled between November 2004 and May 2007. The
median volume of foam used was 8 (range 4e14) ml. Above-knee (AK) and below-knee (BK) GSV
reflux was present in 88 (97%) and 80 (88%) legs respectively prior to treatment. AK and BK-GSV
reflux was completely eradicated by a single session of UGFS in 86 (98%) and 74 (93%) legs
respectively; and by two sessions of UGFS in 88 (100%) and 77 (97%) legs respectively. In those
legs where GSV reflux had been eradicated, recanalisation occurred in 7/78 (9%) AK and 8/68
(12%) BK-GSV segments after 12 months follow-up. Retreatment, where undertaken, with
a single UGFS session effectively eradicated all GSV reflux in all cases of recanalisation.
Discussion: A single session of UGFS can eradicate reflux in the AK and BK-GSV in over 93% of
patients with symptomatic recurrent GSVV. Re-recurrence at 12 months is superior to that
reported after redoGSV surgery, similar to that observed following otherminimally-invasive tech-
niques and, when it occurs, is effectively and simply treated by a single further session of UGFS.
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108 K.A.L. Darvall et al.Introduction (>0.5 s) reflux in a segment of residual AK and/or BK-GSVResidual and/or recurrent great saphenous vein (GSV)
reflux is disappointingly common after superficial venous
surgery (SVS). For many years, authors have reported that
around 20% of patients undergoing SVS for great saphenous
varicose veins (GSVV) have been operated previously for
GSVV in the same leg.1,2 In our current ultrasound-guided
foam sclerotherapy (UGFS) practice we find that figure to
be 21% suggesting that there has been little improvement in
surgical outcomes in recent times.
Recurrence after GSVV surgery may be due to
1. Residual varicose veins (VV) often because of failure to
adequately strip a refluxing above-knee (AK) and
below-knee (BK) GSV at the first operation,3
2. True recurrence, often referred to as neovascularisation.
This can occur at the previously dissected saphenofe-
moral junction (SFJ) or stripping track, or
3. Progression of disease, for example the development of
new reflux in the anterior accessory saphenous vein in
the thigh.
All three pathologies often co-exist in the same patient
and can be difficult to distinguish.
Redo GSVV surgery typically comprises re-exploration of
the SFJ, stripping of the AK-GSVandmultiple phlebectomies.
Such surgery can be technically demanding and associated
with a higher incidence of significant complications and re-
recurrence than first time GSVV surgery.4,5 Furthermore,
reflux in the BK-GSV, a well-recognised cause of recurrence
resulting from a reluctance to strip the BK-GSV for fear of
causing saphenous nerve injury at the first operation,6 is
similarly difficult to treat with further surgery.
Although the role of endovenous laser ablation (EVLA),
radiofrequency ablation (RFA) and UGFS in treating primary
GSVV is well established, their effectiveness in recurrent
GSVV is less well defined.7e15
The aim of the present study, therefore, is to describe
duplex ultrasound (DUS) outcomes 12 months following
UGFS of recurrent GSVV.MethodsPatients
Local ethics committee approval and written informed
consent were obtained. Consecutive UK National Health
Service (NHS) patients referred to AWB and DJA by their
general practitioners between November 2004 and May
2007 because of symptomatic recurrent GSVV were studied.
Recurrence was defined as previous surgery to the GSV in
the same leg on at least one previous occasion. Specifically,
all patients had undergone attempted SFJ ligation and
multiple phlebectomies, with or without attempted strip-
ping of the GSV; in most cases this was to the level of the
knee only.
To be considered suitable for UGFS patients had to have
symptomatic (CEAP C2e6)
16 venous disease (i.e. treatment
was not offered for cosmetic indications) and significanton DUS. Vein size was not a consideration in patient
selection. Patients with absent pedal pulses or an ankle
brachial pressure index <0.9 were excluded as were those
with post-thrombotic deep venous disease.
Pre-treatment assessment
DUS was performed, as previously described,7 at the initial
clinic attendance in order to identify sites of superficial,
deep and communicating venous reflux.
UGFS treatment
Our method of UGFS treatment has been described in detail
previously and is thus summarised here.7 All treatments
took less than 30 min and were performed as office
procedures in a treatment room. The superficial varices and
incompetent truncal veins were marked on the skin using
duplex imaging with the patient standing, and then, with
the patient supine, cannulae were inserted into the truncal
veins under direct ultrasonographic guidance. Sclerosant
foam, prepared by a modified Tessari’s method using two
2 ml syringes connected by a three-way tap and a 5 micron
filter (B Braun Medical, Sheffield, UK), and comprising
0.5 ml of 3% sodium tetradecyl sulphate (STS) (Fibrovein;
STD Pharmaceuticals, Hereford, UK) and 2 ml of air, was
then injected with the leg held in an elevated position.
Aliquots of foam were injected until all target veins were
observed to be in spasm and full of foam on DUS.
With the leg still elevated, compression bandaging was
applied and a thigh-length class II compression stocking
(Credelast; Credenhill, Ilkeston,UK) providing 23e32mmHg
at the ankle applied over the bandage. This was left intact for
five to ten days, depending on the size of the veins, after
which it was removed and the class II stocking worn alone for
the remainder of the first month. All patients were provided
with a 24 h “help-line” number to call at any time following
treatment in case of any concerns.
Outcome measures and follow-up
The aim of treatment was to relieve the symptoms of
venous hypertension.
The chosen primary end-point was, therefore, complete
eradication of superficial venous reflux in the trunk and
major tributaries of the GSV.
All patients were seen at 1, 6 and 12 months after
treatment in a dedicated nurse-led (GRB) research clinic.
Patients were also asked at their first post-treatment visit
whether they had had any problems following treatment.
Specifically they were asked about visual disturbance,
headache, and possible nerve problems in the treated leg.
Phlebitis and skin pigmentation were not recorded.
Repeat DUS was performed at each follow-up visit as per
the pre-treatment duplex. In addition, occlusion of the
treated saphenous trunk was determined by a lack of
compressibility and the absence of any flow. Complete
occlusion was defined as occlusion over the entire length of
the GSV. Recanalisation was defined as the presence of flow
in either an antegrade or retrograde direction in a previously
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complete if over 50% of the length of vein had recanalised.
Where recanalisation was found, the presence or absence of
recurrent reflux was determined.
Patients with residual reflux or recanalisation at any
follow-up appointment were offered further treatment by
repeating foam sclerotherapy with 3% STS as outlined
above.
Results
Patients and treatments
Patient characteristics are shown in Table 1. In 88 legs
there was reflux in the AK-GSV, of which 77 also exhibited
reflux in the BK-GSV; isolated BK-GSV reflux was observed in
only 3 legs.
Despite a previous SFJ dissection as evidenced by
a previous scar, in 27 legs there was an apparently intact and
incompetent SFJ refluxing into an incompetent residual AK-
GSV. In 34 legs the SFJ appeared to have been (at least
partially) ligated and there was collateral reflux into an
incompetent residual AK-GSV through tributaries and/or
neovascularisation. In the remaining 30 legs the SFJ has been
satisfactory ligated and the proximal (usually 5e10 cm)Table 1 Patient and disease characteristics and patterns
of recurrence.
Parameter 73 patients
(91 legs)
Age in years e median (range) 58 (32e86)
Sex
M 24 (33)
F 49 (67)
CEAP clinical grade
C2 54 (59)
C3 4 (4.5)
C4 21 (23)
C5 8 (9)
C6 4 (4.5)
Etiology
Primary (EP) 91 (100)
Secondary (ES) 0 (0)
Anatomical patterns of venous reflux
Superficial and deep (ASD) 5 (5.5)
Superficial only (AS) 86 (94.5)
Recurrent GSV
above and below-knee
77 (84.5)
Recurrent GSV above-knee only 11 (12)
Recurrent GSV below-knee only 3 (3.5)
Pathophysiological classification
Reflux (PR) 91 (100)
Obstruction (PO) 0 (0)
Pattern of recurrence
Incompetent SFJ into GSV 27 (30)
Neovascularization into
proximal thigh GSV
34 (37)
Isolated GSV remnant reflux 30 (33)AK-GSVremovedbut therewas reflux in theAKand/or BK-GSV
trunkbelow this point as a result of perforator incompetence.
One, two, and three cannulae were used to introduce
the foam in 36, 43, and 12 treatments respectively. The
median volume of 3% STS foam used at each treatment was
8 (range 4e14) ml.
There was no clinical or DUS evidence of DVT or PE,
no visual disturbance, or any other complication or side
effects.
Treatment of the AK-GSV
Complete eradication of AK-GSV reflux was achieved in all
88 legs; 86/88 (98%) legs after one treatment and in
a further two legs after a second (course of primary
treatment) (Fig. 1).
Recanalisationwas observed in 0/79 (0%) scanned legs at 6
months and 7/78 (9%) scanned legs at 12months (Fig. 1). Nine
and ten legs were not scanned at 6 and 12 months respec-
tively because the patients defaulted from follow-up.
At 12 months this AK-GSV recanalisation was partial
(<50% length) with reflux in four legs, and complete (>50%)
with reflux in three legs. Of these seven legs, four under-
went one session of repeat UGFS which resulted in
successful complete eradication of AK-GSV reflux, and
three were content with the clinical result and declined
further treatment.
Treatment of the BK-GSV
Complete eradication of reflux in the BK-GSV was achieved
in 77/80 (96.5%) legs; 74 (93%) legs after one, and in
a further three (3.5%) legs after a second, treatment
session (course of primary treatment) (Fig. 2).
In three legs (3.5%), complete eradication of reflux in
the BK-GSV was not achieved after a single treatment
session but these patients, despite residual reflux in the BK-
GSV, were content with the clinical result and declined
further treatment sessions.
In the 77 legs in whom the primary course of UGFS
achieved complete eradication of the reflux in the BK-GSV,
recanalisation was observed in 1/69 (1.5%) scanned legs at
6 months and 8/68 (12%) scanned legs at 12 months (Fig. 2).
Eight and 12 legs were not scanned at 6 and 12 months
respectively.
At 6 months this BK-GSV recanalisation was complete
(>50%) with reflux in the single leg, but the patient was
content with the clinical result and declined further
treatment.
At 12 months this BK-GSV recanalisation was partial
(<50%) with reflux in three legs, and complete with reflux
in five legs. Of these eight legs, three underwent one
session of repeat UGFS which resulted in successful
complete eradication of BK-GSV reflux, and for the
remaining five legs the patient was content with the clinical
result and declined further treatment.
Treatment of the entire GSV
Complete eradication of reflux in the entire (AK and BK)
GSV was achieved in 84/91 (92%) legs after one, and in
Figure 1 Eradication of reflux and recanalisation in the above-knee great saphenous vein (AK-GSV).
110 K.A.L. Darvall et al.a further 4/91 (4.5%) legs after two treatment sessions
(course of primary treatment) (Fig. 3). In three legs (3.5%),
complete eradication of GSV reflux was not achieved by one
treatment session but these patients, despite residual GSV
reflux, were content with the clinical result and declined
further treatment sessions.
In the 88 legs in whom the primary course of UGFS
achieved complete eradication of GSV reflux, recanalisa-
tion was observed in 1/79 (1.5%) legs at 6 months and 9/77(12%) legs at 12 months (Fig. 3). Nine and 11 legs were not
scanned at 6 and 12 months respectively.
At 6 months, the single patient was content with the
clinical result and declined further treatment.
At 12 months, four underwent one session of repeat
UGFS which resulted in successful complete eradication of
GSV reflux, and for the remaining five legs the patient was
content with the clinical result and declined further
treatment.
Figure 2 Eradication of reflux and recanalisation in the below-knee great saphenous vein (BK-GSV).
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Many observers have reported disappointing results with
redo surgery for residual and recurrent GSVV; and most
surgeons would probably prefer not to do such surgery if an
effective alternative could be found.4,5Intuitively, therefore, it is in the treatment or recurrent
VV that one might imagine that the new endovenous
techniques would have their greatest appeal to patients
and surgeons alike. But, somewhat surprisingly, data on the
effectiveness of EVLA, RFA and UGFS for recurrent GSVV are
relatively limited when compared to primary disease.7e15
Figure 3 Eradication of reflux and recanalisation in the entire great saphenous vein (GSV).
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recurrent GSV.17 Fifteen legs had neovascularisation con-
necting with a residual GSV, two had an incompetent thigh
perforator, and one had a refluxing anterior thigh branch
reconnecting with the GSV. They found occlusion of all 18
GSV at one month; and in 16/16 followed up to 12 months.One-third had temporary sensory disturbances. All returned
to daily activities within three days.
Hinchcliffe et al. randomised 16 patients with bilateral
recurrent GSVV to have one leg treated with RFA and the
other with SVS comprising a lateral approach to the SFJ and
GSV strip to the knee.9 All limbs had previously been
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reflux in the GSV on DUS. Prior to randomisation they found
that 70% of patients had a persistent and incompetent GSV
suitable for treatment with RFA. GSV were considered
unsuitable if excessively tortuous, or <3 or >12 mm in
diameter. The patients were followed up to 12 months and
they found complete occlusion in 13/16 GSV treated with
RFA, and complete GSV stripping in 14/16 legs treated with
SVS. RFA was significantly quicker to perform and associ-
ated with less pain and bruising.
van Groenendael et al. retrospectively compared
outcomes in 149 patients who underwent SVS and 67
patients who underwent EVLA for recurrent GSVV.18 All
limbs had a recurrent SFJ and had reflux in a part of the
GSV. In the surgically-treated group 87% had had previous
GSV stripping, and in the EVLA group 57% had had stripping.
All had had previous SFJ disconnection. All treatments were
deemed successful immediately after treatment and in the
46 (69%) legs scanned 8 weeks after EVLA, all treated veins
remained occluded. At a median follow-up of 13.5 months
26% of surgery patients had “clinical recurrence” (although
a definition for this is not given in the paper and repeat DUS
was not performed), compared with 12% in the EVLA group
at a median follow-up of 15 months. After adjusting for
length of follow-up this difference was not statistically
significant. They also found less post-treatment pain in the
surgical group, but more analgesia usage. Wound infection
occurred in 8% of the surgical group. They conclude that “if
anatomically suitable” EVLA is a good treatment alternative
for recurrent GSVV, however, they also point out that only
31% of patients with recurrent GSVV were suitable for EVLA.
Various reasons were given for unsuitability: 37% tortuosity
of the GSV, 8% GSV diameter <4 mm, 4% presence of
thrombophlebitis, 51% other reasons including veins too
branched or superficial and too many connections with the
deep venous system.
Four groups have looked at UGFS for recurrent GSVV.
Kakkos et al. presented immediate results of 45 legs with
recurrent GSVV treated with UGFS (3% STS foam).19 Twenty-
eight had groin reflux, five perforator vein, and the
remainder had isolated GSV remnant reflux. A single injec-
tion of 6 ml was adequate in 58% of legs; 11% needed three or
more treatment sessions. However, complete elimination of
reflux at the end of treatment was only achieved in 39/45
(87%) legs. Follow-up was only for 3 weeks.
Darkeetal. treated18 legswith recurrentGSVVwithUGFS
(3% polidocanol foam).20 All had persistent or reconstituted
GSV trunks in continuity with superficial varicosities and
usuallywith the femoral vein in the groin. Legswere assessed
clinically and with DUS after 6 weeks. Ten legs had complete
occlusion after one treatment; a further five had complete
occlusionafter two treatments. The three remaining legs had
partial occlusion (either GSV still open but varicosities all
closed, or less than complete GSV occlusion but patient
satisfied) after one, two or three treatments.
Coleridge Smith reported his experience with using UGFS
(mostly 3% STS foam) for 267 recurrent GSVV in 2006.21
Further information about the type of recurrence was not
given. One hundred and six legs (40%) were reviewed at
least 6 months (mean 11 months) following treatment. The
GSV was occluded in 98/106 (92%); better than the 86%
occlusion rate seen in primary GSV.O’Hare et al. reviewed 32 legs 6 months after UGFS (3%
STS foam) for recurrent VV.22 They found occlusion of
treated veins on DUS at 6 months in 23/32 (72%) and 28/32
(88%) were satisfied with the results of treatment. Unfor-
tunately, this represented less than 50% of their treated
cohort and they gave no further information regarding the
type of recurrence treated. They also included some
patients treated for SSV rather than GSV recurrence.
In conclusion, the present paper adds further evidence
that UGFS is a safe and clinically effective treatment for
recurrent GSVV. A primary course of UGFS, comprising one
and infrequently two treatment sessions, leads to complete
eradication of GSV reflux in virtually 100% of cases.
Recanalisation at 12 months is superior to that reported
after surgery and similar to that observed following other
minimally-invasive techniques. Recanalisation is easily and
successfully treated with a further single UGFS treatment.Conflict of Interest/Funding
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